Deferroxamine preconditioning promotes long-lasting retinal ischemic tolerance.
about
Oxygen sensing in retinal health and diseaseIron chelation and multiple sclerosisIs there a place for cerebral preconditioning in the clinic?The oral iron chelator deferiprone protects against iron overload-induced retinal degenerationPost-ischemic conditioning in the rat retina is dependent upon ischemia duration and is not additive with ischemic pre-conditioningTransdermal deferoxamine prevents pressure-induced diabetic ulcers.Prophylactic neuroprotection against stroke: low-dose, prolonged treatment with deferoxamine or deferasirox establishes prolonged neuroprotection independent of HIF-1 function.Evidence for a functional adrenomedullin signaling pathway in the mouse retina.Glaucoma-induced degeneration of retinal ganglion cells prevented by hypoxic preconditioning: a model of glaucoma tolerance.The Oral Iron Chelator Deferiprone Protects Against Retinal Degeneration Induced through Diverse Mechanisms.Role of hypoxia-inducible factor-1α in preconditioning-induced protection of retinal ganglion cells in glaucoma.Hypoxia-Inducible Factor-1α Target Genes Contribute to Retinal Neuroprotection.Role of iron in ischemia-induced neurodegeneration: mechanisms and insights.Exercise and Cyclic Light Preconditioning Protect Against Light-Induced Retinal Degeneration and Evoke Similar Gene Expression Patterns.Repetitive hypoxia extends endogenous neurovascular protection for stroke.The Oral Iron Chelator Deferiprone Protects Against Retinal Degeneration Induced through Diverse MechanismsIroning out neurodegeneration: iron chelation for neuroprotectionPreconditioning with volatile anaesthetic sevoflurane in ischemic retinal lesion in rats.
P2860
Q26827518-49352E63-F8EB-4BC9-A61C-33C9524337EFQ27001743-5B923615-287C-4210-82CF-D85378291D54Q33919637-00BDE799-C2EF-4081-AC72-F54E381AC7F2Q34281402-C7AE1B27-3697-4FC8-96B3-E1C35DF28E99Q34293224-66DF5D3E-870B-494B-AD20-84C4F573C043Q34926164-1FFBAAFF-F153-4350-B1C9-505BD30D9432Q35088183-37FFCA3D-44D7-4955-9FA4-A0A6F27BB48BQ36015785-9F40546A-61B4-49D1-A09A-5BFB04CC2BFCQ36071701-4419AD7B-268A-4FC7-B628-AA001549F545Q37149377-F099E44C-B76E-49C3-9504-3A01A87F3E10Q37363949-E7E7C5E9-9CDD-454B-B1BF-38722A36D85BQ37667292-DA5B8257-4656-490D-BE7D-1C97FBE9AC21Q38194946-A22F0697-3B1A-44C7-B1C7-964F070D1291Q40477445-B0DC929D-18CC-4B36-A1D4-338B444C790CQ41991619-5A7FED91-9265-4C8F-B002-07B917C03B37Q42000121-F18DC33D-00D5-49DA-B943-8B0AE6E8F79FQ42663916-0048DC00-1117-4F6F-A2D7-C30ABEB44998Q48155601-2FFBFA6C-35CE-4E26-8586-ECF1D7B1553D
P2860
Deferroxamine preconditioning promotes long-lasting retinal ischemic tolerance.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Deferroxamine preconditioning promotes long-lasting retinal ischemic tolerance.
@en
Deferroxamine preconditioning promotes long-lasting retinal ischemic tolerance.
@nl
type
label
Deferroxamine preconditioning promotes long-lasting retinal ischemic tolerance.
@en
Deferroxamine preconditioning promotes long-lasting retinal ischemic tolerance.
@nl
prefLabel
Deferroxamine preconditioning promotes long-lasting retinal ischemic tolerance.
@en
Deferroxamine preconditioning promotes long-lasting retinal ischemic tolerance.
@nl
P2093
P2860
P356
P1476
Deferroxamine preconditioning promotes long-lasting retinal ischemic tolerance.
@en
P2093
Jeffrey M Gidday
Lihong Zhang
P2860
P304
P356
10.1089/JOP.2008.0082
P577
2008-12-01T00:00:00Z